1 The pharmacokinetics of primaquine have been examined in five healthy volunteers who received single oral doses of 15, 30 and 45 mg of the drug, on separate occasions. Each subject received an i.v. tracer dose of [14C]-primaquine (7.5 ,uCi), simultaneously with the 45 mg oral dose. 2 Absorption of primaquine was virtually complete with a mean absolute bioavailability of 0.96 ± 0.08. 3 Elimination half-life, oral clearance and apparent volume of distribution for both primaquine and the carboxylic acid metabolite were unaffected by either dose size, or route of administration. 4 The relationships between area under the curve and dose size were linear for both primaquine (r = 0.99, P -0.01) and its carboxylic acid metabolite (r = 0.99, P , 0.01). 5 The mean whole blood to plasma concentration ratios were determined for primaquine (0.81), and for the carboxylic acid metabolite of primaquine (0.84). 6 Primaquine is a low clearance compound (CL = 24.2 ± 7.4 1 h-1), is extensively distributed into body tissues (V = 242.9 ± 69.51) and is not subject to extensive first pass metabolism.
Introduction
The antimalarial 8-aminoquinoline derivative, primaquine, has been in clinical use for over 40 years; however, little is known of its pharmacokinetics, particularly in relation to the influence of dose size. The importance of such pharmacokinetic information is underlined by the fact that, therapeutically, primaquine is used in oral daily doses ranging from 15 to 45 mg.
Although the pharmacokinetics of primaquine, after 45 mg oral dosage, has been examined recently (Greaves et al., 1980; Mihaly et al., 1984) neither its disposition after smaller single doses nor its absolute bioavailability have been studied. This is, in part, the consequence of assay limitations which have now been overcome by the recent development of a simple, sensitive (1 ng/ml) selective and reproducible h.p.l.c. method of analysis .
In addition, a study of the absolute bioavailability of primaquine, requires its administration by the intravenous route. It has been proposed that primaquine is subject to extensive first pass hepatic extraction (Greaves et al., 1980) . This implies that i.v. dosage of this drug would be associated with substantially higher plasma drug concentrations than those seen with oral dosage and this could lead to greater pharmacological, and possibly toxic, effects after i.v. administration.
Correspondence: Dr G. W. Mihaly, Gastroenterology Unit, Department of Medicine, Austin Hospital, Heidelberg, Victoria, 3084, Australia Therefore, the purpose of this study was firstly to examine the pharmacokinetics of primaquine over the therapeutic dosage range (15-45 mg) and secondly, to measure its absolute bioavailability. Assay methods (a) Primaquine and the carboxylic acid metabolite of primaquine: Plasma and whole blood concentrations of primaquine and the carboxylic acid metabolite of primaquine, were determined by selective and sensitive h.p.l.c. methods Mihaly et al., 1984 The peak plasma concentration (Cmax) and the time at which it was reached (tmax), the terminal phase elimination rate constant (Xz) the terminal phase half-life (tl,2), the area under the plasma concentration-time curve from time = 0 to 24 h AUC(0,24), the area under the curve from time 0 to infinity (AUC), oral clearance (CL0), systemic clearance (CL), and the volume of distribution (V) were all calculated, as previously described , by standard model independent pharmacokinetic methods (Gibaldi & Perrier, 1975; Rowland & Tozer, 1980 [14C]-primaquine ( Figure 3 ). However, after 30 (Rollo, 1980 (Ward et al., 1984b) . HowYo of the plasma [14]-radioactivity ever, detailed studies in man of the absolute -ounted for by plasma concentra-bioavailability of primaquine and of its pharma-
[14C]-carboxylic acid metabolite, cokinetics across the clinically used dosage range than 5% was due to the parent have not been undertaken.
The results of the present study demonstrated blood to plasma distribution (B/P) that the pharmacokinetics of primaquine, after naquine, and the carboxylic acid oral administration, are unaffected by dose size primaquine were determined at 2 within the clinically used dosage range (Figure  r the simultaneous i.v./oral dose 1; Table 1 ). Therefore, as would be expected, were no significant differences in the extent of formation of the carboxylic acid ndividual, between the 2 and 6 h metabolite of primaquine (as measured by the )rimaquine (B/P at 2 h = 0.81 + ratios of AUCs for this metabolite and the ) h = 0.80 + 0.14), and for the parent drug) was also unaffected by dose size d metabolite of primaquine (B/P at ( Figure 1 ; Table 1 ). These results are in contrast 0.37 and at 6 h = 0.83 + 0.40).
to those cited in the primaquine disposition studies referred to above, and to those found using the isolated perfused rat liver (Ward et al., 1985) . , and that the extent of formation of this metabolite is unaffected by the route of administration. Furthermore, as the AUC for the carboxylic acid derivative is greater than that of the parent drug, the clearance of the metabolite must have been less than that for primaquine. Some antimalarial agents, in particular the 4-aminoquinoline derivative chloroquine, have been shown to concentrate selectively in white and red blood cells resulting in whole blood: plasma concentration ratios of 10:1 (Bergqvist et al., 1983) . We found no evidence for any accumulation of primaquine, or the carboxylic acid metabolite in blood cells. This is in keeping with the exoerythrocytic mode of action of this antimalarial agent (Bruce-Chwatt, 1979) . A detailed evaluation of the distribution characteristics of primaquine into specific blood cell components was not undertaken.
The present study showed that the pharmacokinetics of primaquine and of its carboxylic acid metabolite are independent of both dose size and route of administration and that neither drug nor its carboxylic acid metabolite undergo accumulation into blood cells-unlike other antimalarials. We also showed that primaquine is completely absorbed after oral administration into the systemic circulation and that, in contrast to earlier suggestions, this drug is a low clearance compound which is not subject to extensive first pass hepatic extraction.
